XML 57 R38.htm IDEA: XBRL DOCUMENT
v3.20.1

COMMERCIALIZATION AGREEMENTS (Details) - USD ($) $ in Millions |  | 1 Months Ended | 3 Months Ended |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2019 | Jul. 23, 2018 | Oct. 19, 2017 | Dec. 31, 2019 | Oct. 31, 2015 | Nov. 30, 2009
Recognized revenues related to future milestone payment |  |  |  | $ 4.5 |  |
Future milestone payment | $ 10.0 |  |  | 10.0 |  |
Pfizer [Member] |  |  |  |  |  |
Collaborative Arrangement Profit Share Percentage |  |  |  |  |  | 40.00%
Debt Instrument, Face Amount |  |  |  |  | $ 4.3 |
Chiesi US Agreement [Member] |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable |  | $ 25.0 | $ 25.0 |  |  |
Additional Amounts Payable To Cover Development Costs |  | 20.0 |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  | 7.5 |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  | $ 760.0 |  |  |  |
Chiesi US Agreement [Member] | Maximum [Member] |  |  |  |  |  |
Payment On Net Sales Percentage |  | 40.00% |  |  |  |
Chiesi US Agreement [Member] | Minimum [Member] |  |  |  |  |  |
Payment On Net Sales Percentage |  | 15.00% |  |  |  |
Chiesi Ex US Agreement [Member] |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable |  |  | 25.0 |  |  |
Additional Amounts Payable To Cover Development Costs |  |  | 25.0 |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  |  | 10.0 |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  | $ 320.0 |  |  |
Chiesi Ex US Agreement [Member] | Maximum [Member] |  |  |  |  |  |
Payment On Net Sales Percentage |  |  | 35.00% |  |  |
Chiesi Ex US Agreement [Member] | Minimum [Member] |  |  |  |  |  |
Payment On Net Sales Percentage |  |  | 15.00% |  |  |
Chiesi US Agreement and Chiesi Ex US Agreement [Member] |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable | 50.0 |  |  | $ 50.0 |  |
Payments in consideration for development services performed | 40.1 |  |  |  |  |
Payments in connection with performance of additional studies | $ 9.1 |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement profit sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow for cost incurred in the consideration for development services performed + References No definition available. + Details
Name: | plx_PaymentInConsiderationForDevelopmentServicesPerformed
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for cost incurred in the connection with performance of additional studies. + References No definition available. + Details
Name: | plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |